ASCO 2019 Dr. Richardson on Isatuximab | Int Myeloma Fn
Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma - ScienceDirect
Pomalidomide with dexamethasone direct anti-myeloma effects under... | Download Scientific Diagram
![PDF] Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/be4724496d6a2bc3c1ce363734069c2dc2a77f30/2-Figure1-1.png "PDF] Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. | Semantic Scholar")
PDF] Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. | Semantic Scholar
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial - The Lancet Oncology
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial - The Lancet Oncology
![PDF] Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/c2d9ab11b5739b401b8d3d2d135f5d895e4a8519/14-Figure3-1.png "PDF] Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. | Semantic Scholar")
PDF] Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. | Semantic Scholar
Continued Benefit Observed With Isatuximab Plus Pomalidomide and Dexamethasone in Multiple Myeloma - Cancer Therapy Advisor
Trials
FDA approves Sarclisa regimen for adults with advanced multiple myeloma
ICARIA-MM Study Updates| Int'l Myeloma Foundation
Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma | Haematologica
APOLLO trial results: Addition of daratumumab to pomalidomide + dexamethasone in relapsed/refractory multiple myeloma
3791-Pomalidomide bortezomib and dexamethasone relapsed | eviQ
The real‐world use and efficacy of pomalidomide for relapsed and refractory multiple myeloma in the era of CD38 antibodies - Szabo - eJHaem - Wiley Online Library
Progression-free survival with elotuzumab/pomalidomide/dexamethasone... | Download Scientific Diagram
Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma | Research To Practice
Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma | Research To Practice
Pomalidomide/Dexamethasone Combination in Relapsed/Refractory Multiple Myeloma | Research To Practice
Daratumumab regimen extends PFS among certain patients with relapsed or refractory myeloma
OncLive - Register Today for our next online broadcast: http://www.onclive.com/link/7700 SARCLISA is indicated, in combination with pomalidomide and dexamethasone, for the treatment of patients with multiple myeloma who have received at least
DREAMM Clinical Trial Program
Pomalyst (Pomalidomide) Received a New Indication for Patients with Relapsed and/or Refractory Multiple Myeloma
POMALYST® (pomalidomide) Treatment Option
